4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: Novel antiarrhythmic agents
A series of 4,5-dihydro-1-phenyl-1H-2,4-benzodiazepines has been identified as potential antiarrhythmic agents that interact with sodium and potassium channels and prolong the ventricular effective refractory period (ERP) in anesthetized guinea pigs. Concomitant displacement of radiolabeled bactrach...
Gespeichert in:
Veröffentlicht in: | Journal of medicinal chemistry 1993-10, Vol.36 (22), p.3361-3370 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3370 |
---|---|
container_issue | 22 |
container_start_page | 3361 |
container_title | Journal of medicinal chemistry |
container_volume | 36 |
creator | Johnson, Robert E Baizman, Eugene R Becker, Carolyn Bohnet, Eric A Bell, Rebecca H Birsner, Nancy C Busacca, Carl A Carabateas, Philip M Chadwick, Christopher C |
description | A series of 4,5-dihydro-1-phenyl-1H-2,4-benzodiazepines has been identified as potential antiarrhythmic agents that interact with sodium and potassium channels and prolong the ventricular effective refractory period (ERP) in anesthetized guinea pigs. Concomitant displacement of radiolabeled bactrachotoxin from site II in Na+ channels and of radiolabeled dofetilide from delayed rectifier K+ channels was evident with all members of this chemical series at a concentration of 10 microM. Structure-activity relationship (SAR) studies using a paced guinea pig model to assess prolongation of the ERP indicated that methyl or ethyl at the 1-position had little effect on activity, while larger groups caused a diminution of activity. Compounds with substituents at either the 3- or 4-position that increased lipophilicity generally were more potent; however, too many lipophilic substituents simultaneously at positions 1, 3, and 4 resulted in less active compounds. Substituents on either aromatic ring had little influence on activity, and phenyl at the 5-position resulted in a significant reduction in antiarrhythmic activity. When two sets of enantiomerically pure compounds were tested in the guinea pig, chirality was shown to be important for activity of 8, where the (R)-enantiomer was the more active, but not in the case of 15, where the enantiomers were equiactive. Several compounds in this series increased the threshold for ventricular fibrillation and refractoriness in myocardially-infarcted anesthetized cata and delayed the onset of aconitine-induced arrhythmias in anesthetized guinea pigs following intravenous dosing. Moreover, these compounds possessed oral antiarrhythmic activity in conscious myocardially-infarcted dogs. Compound R-15 has been advanced for further biological and toxicological evaluations. |
doi_str_mv | 10.1021/jm00074a017 |
format | Article |
fullrecord | <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1021_jm00074a017</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_TPS_2PFG4ZG1_S</sourcerecordid><originalsourceid>FETCH-LOGICAL-a383t-fcbd9ffb4e0e285b7be252cfc936d62677e336f8e261855aea74fbc4465d0c2b3</originalsourceid><addsrcrecordid>eNpt0MFPwjAUBvDGaBDRk2cTDiYepNq-dt3wZlDAhCgJePHSdF0rxbGRdhjnX-8MhHjw9A7fLy_vfQidU3JDCdDb5YoQEnNFaHyA2jQCgnlC-CFqEwKAQQA7RichLBvGKLAWaiXACAXRRmPei_CDW9SZLzHF64Up6hzTMYYex6kpvsvMqW-zdoUJd93n8tPkXVVUTnm_qKvFyumuejdFFU7RkVV5MGe72UGvw8f5YIwnL6Onwf0EK5awCludZn1rU26IgSRK49RABNrqPhOZABHHhjFhEwOCJlGkjIq5TTXnIsqIhpR10PV2r_ZlCN5YufZupXwtKZG_dcg_dTT6YqvXm3Rlsr3d_d_kl7tcBa1y61WhXdgzlnBgfd4wvGUuVOZrHyv_IUXM4kjOpzMJ0-GIv42onDX-auuVDnJZbnzRVPLvgT-Mh4Gl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: Novel antiarrhythmic agents</title><source>MEDLINE</source><source>American Chemical Society Publications</source><creator>Johnson, Robert E ; Baizman, Eugene R ; Becker, Carolyn ; Bohnet, Eric A ; Bell, Rebecca H ; Birsner, Nancy C ; Busacca, Carl A ; Carabateas, Philip M ; Chadwick, Christopher C</creator><creatorcontrib>Johnson, Robert E ; Baizman, Eugene R ; Becker, Carolyn ; Bohnet, Eric A ; Bell, Rebecca H ; Birsner, Nancy C ; Busacca, Carl A ; Carabateas, Philip M ; Chadwick, Christopher C</creatorcontrib><description>A series of 4,5-dihydro-1-phenyl-1H-2,4-benzodiazepines has been identified as potential antiarrhythmic agents that interact with sodium and potassium channels and prolong the ventricular effective refractory period (ERP) in anesthetized guinea pigs. Concomitant displacement of radiolabeled bactrachotoxin from site II in Na+ channels and of radiolabeled dofetilide from delayed rectifier K+ channels was evident with all members of this chemical series at a concentration of 10 microM. Structure-activity relationship (SAR) studies using a paced guinea pig model to assess prolongation of the ERP indicated that methyl or ethyl at the 1-position had little effect on activity, while larger groups caused a diminution of activity. Compounds with substituents at either the 3- or 4-position that increased lipophilicity generally were more potent; however, too many lipophilic substituents simultaneously at positions 1, 3, and 4 resulted in less active compounds. Substituents on either aromatic ring had little influence on activity, and phenyl at the 5-position resulted in a significant reduction in antiarrhythmic activity. When two sets of enantiomerically pure compounds were tested in the guinea pig, chirality was shown to be important for activity of 8, where the (R)-enantiomer was the more active, but not in the case of 15, where the enantiomers were equiactive. Several compounds in this series increased the threshold for ventricular fibrillation and refractoriness in myocardially-infarcted anesthetized cata and delayed the onset of aconitine-induced arrhythmias in anesthetized guinea pigs following intravenous dosing. Moreover, these compounds possessed oral antiarrhythmic activity in conscious myocardially-infarcted dogs. Compound R-15 has been advanced for further biological and toxicological evaluations.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm00074a017</identifier><identifier>PMID: 8230126</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Animals ; Anti-Arrhythmia Agents - chemical synthesis ; Anti-Arrhythmia Agents - pharmacology ; Antiarythmic agents ; Arrhythmias, Cardiac - drug therapy ; Benzodiazepines - chemical synthesis ; Benzodiazepines - pharmacology ; Biological and medical sciences ; Cardiovascular system ; Cats ; Disease Models, Animal ; Dogs ; Guinea Pigs ; Heart Ventricles - drug effects ; Male ; Medical sciences ; Myocardial Contraction - drug effects ; Myocardial Contraction - physiology ; Myocardial Infarction - drug therapy ; Pharmacology. Drug treatments ; Potassium Channels - drug effects ; Potassium Channels - physiology ; Rats ; Rats, Sprague-Dawley ; Refractory Period, Electrophysiological - drug effects ; Sodium Channels - drug effects ; Sodium Channels - physiology ; Structure-Activity Relationship</subject><ispartof>Journal of medicinal chemistry, 1993-10, Vol.36 (22), p.3361-3370</ispartof><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a383t-fcbd9ffb4e0e285b7be252cfc936d62677e336f8e261855aea74fbc4465d0c2b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm00074a017$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm00074a017$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3842394$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8230126$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Johnson, Robert E</creatorcontrib><creatorcontrib>Baizman, Eugene R</creatorcontrib><creatorcontrib>Becker, Carolyn</creatorcontrib><creatorcontrib>Bohnet, Eric A</creatorcontrib><creatorcontrib>Bell, Rebecca H</creatorcontrib><creatorcontrib>Birsner, Nancy C</creatorcontrib><creatorcontrib>Busacca, Carl A</creatorcontrib><creatorcontrib>Carabateas, Philip M</creatorcontrib><creatorcontrib>Chadwick, Christopher C</creatorcontrib><title>4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: Novel antiarrhythmic agents</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>A series of 4,5-dihydro-1-phenyl-1H-2,4-benzodiazepines has been identified as potential antiarrhythmic agents that interact with sodium and potassium channels and prolong the ventricular effective refractory period (ERP) in anesthetized guinea pigs. Concomitant displacement of radiolabeled bactrachotoxin from site II in Na+ channels and of radiolabeled dofetilide from delayed rectifier K+ channels was evident with all members of this chemical series at a concentration of 10 microM. Structure-activity relationship (SAR) studies using a paced guinea pig model to assess prolongation of the ERP indicated that methyl or ethyl at the 1-position had little effect on activity, while larger groups caused a diminution of activity. Compounds with substituents at either the 3- or 4-position that increased lipophilicity generally were more potent; however, too many lipophilic substituents simultaneously at positions 1, 3, and 4 resulted in less active compounds. Substituents on either aromatic ring had little influence on activity, and phenyl at the 5-position resulted in a significant reduction in antiarrhythmic activity. When two sets of enantiomerically pure compounds were tested in the guinea pig, chirality was shown to be important for activity of 8, where the (R)-enantiomer was the more active, but not in the case of 15, where the enantiomers were equiactive. Several compounds in this series increased the threshold for ventricular fibrillation and refractoriness in myocardially-infarcted anesthetized cata and delayed the onset of aconitine-induced arrhythmias in anesthetized guinea pigs following intravenous dosing. Moreover, these compounds possessed oral antiarrhythmic activity in conscious myocardially-infarcted dogs. Compound R-15 has been advanced for further biological and toxicological evaluations.</description><subject>Animals</subject><subject>Anti-Arrhythmia Agents - chemical synthesis</subject><subject>Anti-Arrhythmia Agents - pharmacology</subject><subject>Antiarythmic agents</subject><subject>Arrhythmias, Cardiac - drug therapy</subject><subject>Benzodiazepines - chemical synthesis</subject><subject>Benzodiazepines - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Cats</subject><subject>Disease Models, Animal</subject><subject>Dogs</subject><subject>Guinea Pigs</subject><subject>Heart Ventricles - drug effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Myocardial Contraction - drug effects</subject><subject>Myocardial Contraction - physiology</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Potassium Channels - drug effects</subject><subject>Potassium Channels - physiology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Refractory Period, Electrophysiological - drug effects</subject><subject>Sodium Channels - drug effects</subject><subject>Sodium Channels - physiology</subject><subject>Structure-Activity Relationship</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0MFPwjAUBvDGaBDRk2cTDiYepNq-dt3wZlDAhCgJePHSdF0rxbGRdhjnX-8MhHjw9A7fLy_vfQidU3JDCdDb5YoQEnNFaHyA2jQCgnlC-CFqEwKAQQA7RichLBvGKLAWaiXACAXRRmPei_CDW9SZLzHF64Up6hzTMYYex6kpvsvMqW-zdoUJd93n8tPkXVVUTnm_qKvFyumuejdFFU7RkVV5MGe72UGvw8f5YIwnL6Onwf0EK5awCludZn1rU26IgSRK49RABNrqPhOZABHHhjFhEwOCJlGkjIq5TTXnIsqIhpR10PV2r_ZlCN5YufZupXwtKZG_dcg_dTT6YqvXm3Rlsr3d_d_kl7tcBa1y61WhXdgzlnBgfd4wvGUuVOZrHyv_IUXM4kjOpzMJ0-GIv42onDX-auuVDnJZbnzRVPLvgT-Mh4Gl</recordid><startdate>19931029</startdate><enddate>19931029</enddate><creator>Johnson, Robert E</creator><creator>Baizman, Eugene R</creator><creator>Becker, Carolyn</creator><creator>Bohnet, Eric A</creator><creator>Bell, Rebecca H</creator><creator>Birsner, Nancy C</creator><creator>Busacca, Carl A</creator><creator>Carabateas, Philip M</creator><creator>Chadwick, Christopher C</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19931029</creationdate><title>4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: Novel antiarrhythmic agents</title><author>Johnson, Robert E ; Baizman, Eugene R ; Becker, Carolyn ; Bohnet, Eric A ; Bell, Rebecca H ; Birsner, Nancy C ; Busacca, Carl A ; Carabateas, Philip M ; Chadwick, Christopher C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a383t-fcbd9ffb4e0e285b7be252cfc936d62677e336f8e261855aea74fbc4465d0c2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Animals</topic><topic>Anti-Arrhythmia Agents - chemical synthesis</topic><topic>Anti-Arrhythmia Agents - pharmacology</topic><topic>Antiarythmic agents</topic><topic>Arrhythmias, Cardiac - drug therapy</topic><topic>Benzodiazepines - chemical synthesis</topic><topic>Benzodiazepines - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Cats</topic><topic>Disease Models, Animal</topic><topic>Dogs</topic><topic>Guinea Pigs</topic><topic>Heart Ventricles - drug effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Myocardial Contraction - drug effects</topic><topic>Myocardial Contraction - physiology</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Potassium Channels - drug effects</topic><topic>Potassium Channels - physiology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Refractory Period, Electrophysiological - drug effects</topic><topic>Sodium Channels - drug effects</topic><topic>Sodium Channels - physiology</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Johnson, Robert E</creatorcontrib><creatorcontrib>Baizman, Eugene R</creatorcontrib><creatorcontrib>Becker, Carolyn</creatorcontrib><creatorcontrib>Bohnet, Eric A</creatorcontrib><creatorcontrib>Bell, Rebecca H</creatorcontrib><creatorcontrib>Birsner, Nancy C</creatorcontrib><creatorcontrib>Busacca, Carl A</creatorcontrib><creatorcontrib>Carabateas, Philip M</creatorcontrib><creatorcontrib>Chadwick, Christopher C</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Johnson, Robert E</au><au>Baizman, Eugene R</au><au>Becker, Carolyn</au><au>Bohnet, Eric A</au><au>Bell, Rebecca H</au><au>Birsner, Nancy C</au><au>Busacca, Carl A</au><au>Carabateas, Philip M</au><au>Chadwick, Christopher C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: Novel antiarrhythmic agents</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>1993-10-29</date><risdate>1993</risdate><volume>36</volume><issue>22</issue><spage>3361</spage><epage>3370</epage><pages>3361-3370</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>A series of 4,5-dihydro-1-phenyl-1H-2,4-benzodiazepines has been identified as potential antiarrhythmic agents that interact with sodium and potassium channels and prolong the ventricular effective refractory period (ERP) in anesthetized guinea pigs. Concomitant displacement of radiolabeled bactrachotoxin from site II in Na+ channels and of radiolabeled dofetilide from delayed rectifier K+ channels was evident with all members of this chemical series at a concentration of 10 microM. Structure-activity relationship (SAR) studies using a paced guinea pig model to assess prolongation of the ERP indicated that methyl or ethyl at the 1-position had little effect on activity, while larger groups caused a diminution of activity. Compounds with substituents at either the 3- or 4-position that increased lipophilicity generally were more potent; however, too many lipophilic substituents simultaneously at positions 1, 3, and 4 resulted in less active compounds. Substituents on either aromatic ring had little influence on activity, and phenyl at the 5-position resulted in a significant reduction in antiarrhythmic activity. When two sets of enantiomerically pure compounds were tested in the guinea pig, chirality was shown to be important for activity of 8, where the (R)-enantiomer was the more active, but not in the case of 15, where the enantiomers were equiactive. Several compounds in this series increased the threshold for ventricular fibrillation and refractoriness in myocardially-infarcted anesthetized cata and delayed the onset of aconitine-induced arrhythmias in anesthetized guinea pigs following intravenous dosing. Moreover, these compounds possessed oral antiarrhythmic activity in conscious myocardially-infarcted dogs. Compound R-15 has been advanced for further biological and toxicological evaluations.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>8230126</pmid><doi>10.1021/jm00074a017</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 1993-10, Vol.36 (22), p.3361-3370 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_crossref_primary_10_1021_jm00074a017 |
source | MEDLINE; American Chemical Society Publications |
subjects | Animals Anti-Arrhythmia Agents - chemical synthesis Anti-Arrhythmia Agents - pharmacology Antiarythmic agents Arrhythmias, Cardiac - drug therapy Benzodiazepines - chemical synthesis Benzodiazepines - pharmacology Biological and medical sciences Cardiovascular system Cats Disease Models, Animal Dogs Guinea Pigs Heart Ventricles - drug effects Male Medical sciences Myocardial Contraction - drug effects Myocardial Contraction - physiology Myocardial Infarction - drug therapy Pharmacology. Drug treatments Potassium Channels - drug effects Potassium Channels - physiology Rats Rats, Sprague-Dawley Refractory Period, Electrophysiological - drug effects Sodium Channels - drug effects Sodium Channels - physiology Structure-Activity Relationship |
title | 4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: Novel antiarrhythmic agents |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T10%3A52%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines:%20Novel%20antiarrhythmic%20agents&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Johnson,%20Robert%20E&rft.date=1993-10-29&rft.volume=36&rft.issue=22&rft.spage=3361&rft.epage=3370&rft.pages=3361-3370&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm00074a017&rft_dat=%3Cistex_cross%3Eark_67375_TPS_2PFG4ZG1_S%3C/istex_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8230126&rfr_iscdi=true |